PMID- 30609721
OWN - NLM
STAT- MEDLINE
DCOM- 20191209
LR  - 20220408
IS  - 2073-4409 (Print)
IS  - 2073-4409 (Electronic)
IS  - 2073-4409 (Linking)
VI  - 8
IP  - 1
DP  - 2019 Jan 2
TI  - mTOR: A Cellular Regulator Interface in Health and Disease.
LID - 10.3390/cells8010018 [doi]
LID - 18
AB  - The mechanistic target of Rapamycin (mTOR) is a ubiquitously-conserved 
      serine/threonine kinase, which has a central function in integrating growth 
      signals and orchestrating their physiologic effects on cellular level. mTOR is 
      the core component of differently composed signaling complexes that differ in 
      protein composition and molecular targets. Newly identified classes of mTOR 
      inhibitors are being developed to block autoimmune diseases and transplant 
      rejections but also to treat obesity, diabetes, and different types of cancer. 
      Therefore, the selective and context-dependent inhibition of mTOR activity itself 
      might come into the focus as molecular target to prevent severe diseases and 
      possibly to extend life span. This review provides a general introduction to the 
      molecular composition and physiologic function of mTOR complexes as part of the 
      Special Issue "2018 Select Papers by Cells' Editorial Board Members".
FAU - Boutouja, Fahd
AU  - Boutouja F
AD  - Biochemie Intrazellularer Transportprozesse, Ruhr-Universitat Bochum, 44801 
      Bochum, Germany. fahd.boutouja@rub.de.
FAU - Stiehm, Christian M
AU  - Stiehm CM
AD  - Biochemie Intrazellularer Transportprozesse, Ruhr-Universitat Bochum, 44801 
      Bochum, Germany. Christian.stiehm@rub.de.
FAU - Platta, Harald W
AU  - Platta HW
AD  - Biochemie Intrazellularer Transportprozesse, Ruhr-Universitat Bochum, 44801 
      Bochum, Germany. harald.platta@rub.de.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20190102
PL  - Switzerland
TA  - Cells
JT  - Cells
JID - 101600052
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 1)
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 2)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - *Aging/drug effects/metabolism
MH  - Animals
MH  - *Autoimmune Diseases/drug therapy/metabolism
MH  - *Diabetes Mellitus/drug therapy/metabolism
MH  - Humans
MH  - Mechanistic Target of Rapamycin Complex 1/antagonists & inhibitors/metabolism
MH  - Mechanistic Target of Rapamycin Complex 2/antagonists & inhibitors/metabolism
MH  - *Neoplasms/drug therapy/metabolism
MH  - *Obesity/drug therapy/metabolism
MH  - Signal Transduction
MH  - *TOR Serine-Threonine Kinases/antagonists & inhibitors/physiology
PMC - PMC6356367
OTO - NOTNLM
OT  - aging
OT  - autophagy
OT  - cancer
OT  - kinase
OT  - mTOR
OT  - phosphorylation
COIS- The authors declare no conflict of interest, financial or otherwise.
EDAT- 2019/01/06 06:00
MHDA- 2019/01/06 06:01
PMCR- 2019/01/01
CRDT- 2019/01/06 06:00
PHST- 2018/12/10 00:00 [received]
PHST- 2018/12/25 00:00 [revised]
PHST- 2019/01/01 00:00 [accepted]
PHST- 2019/01/06 06:00 [entrez]
PHST- 2019/01/06 06:00 [pubmed]
PHST- 2019/01/06 06:01 [medline]
PHST- 2019/01/01 00:00 [pmc-release]
AID - cells8010018 [pii]
AID - cells-08-00018 [pii]
AID - 10.3390/cells8010018 [doi]
PST - epublish
SO  - Cells. 2019 Jan 2;8(1):18. doi: 10.3390/cells8010018.